Literature DB >> 35821344

Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma.

Yifei Zhang1,2, Amandeep Godara3, Stacey Pan4, Denis Toskic5, Hashim Mann5,4, Douglas Sborov3, Raymond Comenzo5,4, Ankit Kansagra6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35821344     DOI： 10.1007/s00277-022-04890-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   4.030


× No keyword cloud information.
  1 in total

1.  High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Authors:  Jahanzaib Khwaja; Joshua Bomsztyk; Shameem Mahmood; Brendan Wisniowski; Raakhee Shah; Anish Tailor; Kwee Yong; Rakesh Popat; Neil Rabin; Charalampia Kyriakou; Jonathan Sive; Simona Degli Esposti; Daniel F P Larkin; Sarah Worthington; Alyse Hart; Emma Dowling; Nuno Correia; Ceri Bygrave; Andrzej Rydzewski; Krzysztof Jamroziak; Ashutosh D Wechalekar
Journal:  Blood Cancer J       Date:  2022-09-05       Impact factor: 9.812
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.